Abstract:Objective: Heart failure is a common cardiovascular disease, and its prevalence is increasing year by year. For patients with heart failure combined with non-valvular reduced ejection fraction, drug therapy has always been a key treatment. This study aimed to explore the clinical efficacy of sacubitril valsartan sodium and enalapril in such patients. Methods: Study design: This study used a prospective observational design. From February 2020 to February 2022, we included 123 patients with non-valvular heart failure and reduced ejection fraction who were treated in Xingtai Third Hospital. Patients were divided into two groups according to the treatment plan: Group A (n=61) received enalapril, and Group B (n=62) received nifedipine. All patients received conventional treatment. We compared the efficacy of the two groups of patients 8 weeks after treatment. During the study, the laboratory indicators, echocardiographic indicators, cardiovascular markers, and possible adverse reactions of the two groups of patients before and after treatment were recorded. Results: After 8 weeks of treatment, the effective rate of group B was higher than group A (P < .05). There were no differences in the levels of total protein, total bilirubin, total cholesterol and serum creatinine between the two groups before and after treatment (P > .05). The serum creatinine level in the two groups after treatment was higher than that before treatment, and the level in group B was lower than that in group A (P < .05). There were no statistically significant differences in the levels of total protein, total bilirubin and total cholesterol between the two groups before and after treatment (P > .05), and there was no statistically significant difference in the level of serum creatinine between the two groups before treatment (P > .05), and the level of serum creatinine after treatment was higher than that before treatment, and the level of group B was lower than that of group A (P < .05). Before treatment, there was no significant difference in the levels of high-sensitive troponin T and n-terminal brain natriuretic peptide and cyclic guanosine phosphate between the two groups (P > .05). After treatment, the levels of high-sensitive troponin T and N-terminal brain natriuretic peptide in the two groups were lower than those before treatment, and those in group B were lower than those in group A. The level of cyclic guanosine phosphate in group A was lower than that before treatment, the level of cyclic guanosine phosphate in group B was higher than that before treatment, and the level of group B was higher than that of group A (P < .05). The incidence of adverse cardiovascular events in group B was lower than that in group A (P < .05).In this study, the effective rate of treatment group B was significantly higher than that of treatment group A, indicating that treatment group B had a better therapeutic effect. In addition, there were no significant differences between the two groups in a series of biochemical parameters, but it is worth noting that after treatment, the serum creatinine level of group B was significantly lower than that of group A, which may indicate that the treatment of group B is not only more effective but also Reduces the risk of certain adverse cardiovascular events. Conclusion: The main findings of the study showed that Sacubitril valsartan sodium showed better clinical efficacy than enalapril in patients with heart failure and non-valvular reduced ejection fraction. Specifically, the drug significantly improved patients' kidney function, reduced cardiovascular marker levels, and reduced the incidence of adverse cardiovascular events. These findings have important clinical implications for guiding treatment selection in patients with heart failure.

The Efficacy of Losartan on Renin-Angiotension System of Patients with Congestive Heart Failure

Endothelial Dysfunction in Patients with Congestive Heart Failure Caused by Coronary Heart Disease and the Effect of Losartan on Endothelial Function.

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

The comparison of captopril and losartan in the treatment of heart failure and to the vascular endothelial function of heart failure patients

The Effects of ACE Inhibitor and Angiotensin II Receptor Antagoniston Atrial Natriuretic Factor and Renin-angiotensin Systemin Patients' Plasma with Chronic Renal Failure

Effect of Losartan Treatment on Alleviating Hypertension to the Goal and Left Ventricular Diastolic Dysfunction

Losartan, Captopril and Combined Administration on the Treatment of Atherosclerotic Renal Vascular Disease

Combined therappy of captopril and spironolactone for refractoroy congestive heart failure

Recent Curative Effect of Combining Enalapril with Aldactone in the Treatment of Chronic Heart Failure

The Effects of Telmisartan on Congestive Heart Failure and Its Influence to AngiotensinⅡand Natriuretic Peptide

Effect of angiotensin-Ⅱ-receptor antagonists used in patients with chronic congestive heart failure

A Multi-Center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Chinese Patients with Symptomatic Heart Failure Intolerant of Angiotensin Converting Enzyme Inhibitor Treatment.

Effect of angiotensin converting enzyme inhibitor and angiotensin Ⅱ receptor blocker on renin-angiotensin system in patients with chronic kidney disease

Losartan attenuates ventricular remodeling and protects heart function in rats with chronic heart failure

Investigation of the efficacy of beta-blockers and reninangiotensin-aldosterone system inhibitors in chronic heart failure with preserved ejection fraction

A Comparative Analysis of the Clinical Efficacy of Sacubitril Valsartan Sodium and Enalapril in Patients with Non-Valvular Ejection Fraction Reduction in Heart Failure

Effects of monolithic compound preparations based on angiotensin II receptor antagonist on the prognosis of patients with hypertension

Efficacy of Losartan versus Enalapril in Treatment of Mild and Moderate Hypertension

Effect of Losartan and Captopril on Expression of Cardiac Angiotensin II AT1 Receptor Mrna in Rats Following Myocardial Infarction.

Effects of Losartan on Left Ventricular Hypertrophy and Left Veutricular Diastolic Function in Hypertension

Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease